CG Invites Co., Ltd. (KOSDAQ:083790)

Market Cap	108.65B
Revenue (ttm)	13.62B
Net Income (ttm)	-44.85B
Shares Out	76.89M
EPS (ttm)	-584.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,635
Average Volume	174,280
Open	1,420.00
Previous Close	1,413.00
Day's Range	1,401.00 - 1,477.00
52-Week Range	1,370.00 - 2,640.00
Beta	0.29
RSI	43.51
Earnings Date	Nov 14, 2025

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 87
• Stock Exchange: KOSDAQ
• Ticker Symbol: 083790

Financial Performance

In 2024, CG Invites's revenue was 7.25 billion, an increase of 48.67% compared to the previous year's 4.88 billion. Losses were -51.54 billion, 5.36% more than in 2023.